Advertisement

Amyloid: From Starch to Finish

      SEE CORRESPONDING ARTICLE ON PAGE 797
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kyle R.A.
        Amyloidosis: A convoluted story.
        Br J Haematol. 2001; 114: 529-538
        • Riek R.
        • Eisenberg D.S.
        The activities of amyloids from a structural perspective.
        Nature. 2016; 539: 227-235
        • Berrios G.E.
        Alzheimer’s disease: A conceptual history.
        Int J Geriatr Psychiatry. 1990; 5: 355-365
        • Maurer K.
        • Volk S.
        • Gerbaldo H.
        Auguste D and Alzheimer’s disease.
        Lancet. 1997; 349: 1546-1549
        • Thal D.R.
        • Braak H.
        Post-mortem diagnosis of Alzheimer’s disease [in German].
        Pathologe. 2005; 26: 201-213
        • Spires-Jones T.L.
        • Hyman B.T.
        The intersection of amyloid beta and tau at synapses in Alzheimer’s disease.
        Neuron. 2014; 82: 756-771
        • Di Meco A.
        • Curtis M.E.
        • Lauretti E.
        • Praticò D.
        Autophagy dysfunction in Alzheimer’s disease: Mechanistic insights and new therapeutic opportunities.
        Biol Psychiatry. 2020; 87: 797-807
        • Arnsten A.F.T.
        • Datta D.
        • Leslie S.
        • Yang S.T.
        • Wang M.
        • Nairn A.C.
        Alzheimer’s-like pathology in aging rhesus macaques: Unique opportunity to study the etiology and treatment of Alzheimer’s disease.
        Proc Natl Acad Sci U S A. 2019; 116: 26230-26238
        • van Dyck C.H.
        Anti-amyloid-β monoclonal antibodies for Alzheimer’s disease: Pitfalls and promise.
        Biol Psychiatry. 2018; 83: 311-319
        • Congdon E.E.
        • Sigurdsson E.M.
        Tau-targeting therapies for Alzheimer disease.
        Nat Rev Neurol. 2018; 14: 399-415

      Linked Article

      • Autophagy Dysfunction in Alzheimer’s Disease: Mechanistic Insights and New Therapeutic Opportunities
        Biological PsychiatryVol. 87Issue 9
        • Preview
          Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive memory loss due to aberrant accumulation of misfolded proteins inside and outside neurons and glial cells, leading to a loss of cellular protein homeostasis. Today, no therapy is available to block or slow down AD progression, and the mechanisms of the disease are not fully understood. Autophagy is an intracellular degradation pathway crucial to maintaining cellular homeostasis by clearing damaged organelles, pathogens, and unwanted protein aggregates.
        • Full-Text
        • PDF